Literature DB >> 805178

Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera.

J M Griffiss.   

Abstract

Humoral IgA, separated and purified from human sera drawn 12, 27, and 33 days after infection with serogroups B, Y, and C meningococci, respectively, has been shown to inhibit complement-mediated bacteriolysis by IgG and IgM purified from the same sera. Inhibition was dependent on the ratio of lytic to blocking antibody, was strain specific, and was greater for IgG than IgM. IgM was found to be more active than IgG in a bactericidal test. Activity of IgA appeared unrelated to the presence of a prozone in the whole serum. Similar inhibition was noted for IgA separated from rabbit sera.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 805178

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  T and B cell responses following immunization with tetanus toxoid in IgA nephropathy.

Authors:  F Fortune; M Courteau; D G Williams; T Lehner
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.

Authors:  G A Jarvis; N A Vedros
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

3.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

4.  Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing.

Authors:  R M Hamadeh; M M Estabrook; P Zhou; G A Jarvis; J M Griffiss
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

6.  The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.

Authors:  C M Kahler; L E Martin; G C Shih; M M Rahman; R W Carlson; D S Stephens
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera.

Authors:  G K Schoolnik; T M Buchanan; K K Holmes
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

9.  Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis.

Authors:  David S. Stephens; Shanta M. Zimmer
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

10.  Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis.

Authors:  Terry Guthrie; Simon Y C Wong; Bin Liang; Lisa Hyland; Sam Hou; E Arne Høiby; Svein Rune Andersen
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.